NCT06414590 - Neoadjuvant Tebentafusp for Uveal Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 5, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

March 31, 2032

Conditions

Locally Advanced Unresectable Uveal Melanoma

Interventions

DRUG

Tebentafusp-Tebn

Tebentafusp will be administered as follows: 20mcg on Day 1, 30mcg on Day 8, 68 mcg on Day 15, and weekly doses of 68 mcg thereafter.

Trial Locations (2)

RECRUITING

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

ACTIVE_NOT_RECRUITING

Wills Eye Hospital, Philadelphia

All Listed Sponsors

lead

Thomas Jefferson University

OTHER